Press releases
- FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
- Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
- Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
- Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
- New Survey: Patients and Physicians Overwhelmingly Agree Blood Tests Could Help Close the Colorectal Cancer Screening Gap
- Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
- Guardant Health to Participate in Upcoming Investor Conferences
More ▼
Key statistics
On Friday, Guardant Health (GH*:MEX) closed at 318.41, 8.37% above its 52-week low of 293.83, set on Mar 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 318.41 |
---|---|
High | 318.41 |
Low | 318.41 |
Bid | 309.67 |
Offer | 318.45 |
Previous close | 309.67 |
Average volume | 538.89 |
---|---|
Shares outstanding | 121.89m |
Free float | 116.83m |
P/E (TTM) | -- |
Market cap | 2.30bn USD |
EPS (TTM) | -4.28 USD |
Data delayed at least 20 minutes, as of May 03 2024 19:10 BST.
More ▼